Immune activation in the central nervous system of ME/CFS found by cytokine network analysis of cerebrospinal fluid

Research abstract:

Myalgic encephalomyelitis/chronic fatigue syndrome is an unexplained debilitating disorder that is frequently associated with cognitive and motor dysfunction.

We analyzed cerebrospinal fluid from 32 cases, 40 subjects with multiple sclerosis and 19 normal subjects frequency-matched for age and sex using a 51-plex cytokine assay.

Group-specific differences were found for the majority of analytes with an increase in cases of CCL11 (eotaxin), a chemokine involved in eosinophil recruitment. Network analysis revealed an inverse relationship between interleukin 1 receptor antagonist and colony-stimulating factor 1, colony-stimulating factor 2 and interleukin 17F, without effects on interleukin 1α or interleukin 1β, suggesting a disturbance in interleukin 1 signaling.

Our results indicate a markedly disturbed immune signature in the cerebrospinal fluid of cases that is consistent with immune activation in the central nervous system, and a shift toward an allergic or T helper type-2 pattern associated with autoimmunity.

Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome, by M Hornig, G Gottschalk, D L Peterson, K K Knox, A F Schultz, M L Eddy, X Che and W I Lipkin  in Molecular Psychiatry 21, 261-269 February 2016

Full article

Posted in News | Tagged , , , , , , , , | Comments Off on Immune activation in the central nervous system of ME/CFS found by cytokine network analysis of cerebrospinal fluid

Developing case definitions for ME and CFS using practical experience and consensus

Research abstract:

Background:
There has been considerable controversy regarding how to name and define the illnesses known as myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS). The Institute of Medicine (IOM) report has proposed new clinical criteria and a new name for this illness, but aspects of these recommendations have been scrutinized by patients and
scientists.

Purpose:
It is possible that both empiric and consensus approaches could be used to help settle some of these diagnostic challenges. Using patient samples collected in the USA, Great Britain, and Norway (N = 556), the current study attempted to categorize patients using more general as well as more restricted case definitions.

Results:
Overall, the outcomes suggest that there might be four groupings of patients, with the broadest category involving those with chronic fatigue (N = 62), defined by six or more months of fatigue which cannot be explained by medical or psychiatric conditions. A second category involves those patients who have chronic fatigue that can be explained
by a medical or psychiatric condition (N = 47).

A third category involves more specific criteria that have been posited both by the IOM report, Canadian Clinical Case criteria, ME-ICC criteria and a more empiric approach. These efforts have specified domains of substantial reductions of activity, post-exertional malaise, neurocognitive  impairment, and sleep dysfunction (N = 346). Patients with these characteristics were more functionally impaired than those meeting just chronic fatigue criteria, p < .05. Finally, those meeting even more restrictive ME criteria proposed by Ramsay, identified a smaller and even more impaired group, p < .05.

Conclusion:
It is important that scientists world-wide develop consensus on how to identify and classify patients using clinical and research criteria, and ultimately develop subtypes within such categories.

Case definitions integrating empiric and consensus perspectives, by Leonard A. Jason, Stephanie McManimen, Madison Sunnquist, Abigail Brown, Jacob Furst, Julia L. Newton & Elin Bolle Strand in Fatigue: Biomedicine, Health & Behavior, January 19, 2016

Posted in News | Tagged , , , , | Comments Off on Developing case definitions for ME and CFS using practical experience and consensus

Healthwise Wales study

HealthWise Wales is a Welsh Government initiative to involve everyone in Wales in improving the health and wellbeing of the population, by taking part in research.

They are asking you to:

  • Help them to work out the most important questions on health, wellbeing, and health and social care that they should ask.
  • Tell them your own information, as a member of the Welsh population, to help us answer these questions.

They would like as many people as possible to take part – whatever your age, wherever you live, whether you’re healthy or unwell.

Find out more about what is involved, data protection, the value of large scale studies etc. at their website

BBC news item, 29 Feb 2016: HealthWise Wales survey on nation’s future health needs

Posted in News | Tagged , , , | Comments Off on Healthwise Wales study

Overview of evidence for biochemical muscle abnormality in CFS

Review article abstract:

Introduction: Chronic fatigue syndrome/ Myalgic Encephalomyelitis (CFS/ME) is a
debilitating disorder of unknown aetiology and is characterised by severe disabling fatigue in  the absence of an alternative diagnosis.

Historically, there has been a tendency to draw psychological explanations for the origin of fatigue, however this model is at odds with findings that fatigue and accompanying symptoms may be explained by central and peripheral pathophysiological mechanisms, including effects of the immune, oxidative, mitochondrial and neuronal pathways. For example, patient descriptions of their fatigue regularly cite difficulty in maintaining muscle activity due to perceived lack of energy.

This narrative review examines the literature for evidence of biochemical dysfunction in CFS/ME at the skeletal muscle level.

Methods: This narrative review examines literature following searches of PUB MED,
MEDLINE and Google scholar, using key words such as (e.g. CFS,ME, Immune,
autoimmune, mitochondria, muscle, acidosis).

Results: Studies show evidence for skeletal muscle bio-chemical abnormality in CFS/ME
patients. Following a low-level repeat exercise protocol CFS/ME patients exhibited a
significantly greater muscular acidosis in addition to a slowed time to recovery from acidosis. There is also evidence for impaired AMPK activation following electrical pulse stimulation in CFS/ME patient myotube samples.

Discussion: Bio-energetic peripheral muscle dysfunction is evident in CFS/ME, with a
tendency towards an over-utilisation of the lactate dehydrogenase pathway during low-level exercise, in addition to delayed acid clearance post-exercise. AMPK activation is impaired in CFS/ME myotube samples following electrical pulse stimulation. Potentially, these biochemical abnormalities may lead to the perception of severe muscular fatigue in CFS/ME.

Understanding muscle dysfunction in Chronic Fatigue Syndrome, by Gina Rutherford, Philip Manning, and Julia L Newton in Journal of aging research, 13 January 2016

 

 

Posted in News | Tagged , , , , , | Comments Off on Overview of evidence for biochemical muscle abnormality in CFS

Chronic fatigue affects 1.9% of 16 year olds & is more common with family adversity

Research abstract:

BACKGROUND: In the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort, chronic disabling fatigue lasting ≥6 months affected 1.3% of 13-year-olds, was equally common in boys and girls, and became more prevalent with increasing family adversity.

METHODS: ALSPAC data were used to estimate the prevalence of chronic fatigue syndrome (CFS) at age 16 years, defined by parental report of unexplained disabling fatigue lasting ≥6 months. We investigated gender and a composite 14-item family adversity index as risk factors. School absence data were obtained from the National Pupil Database. Multiple imputation was used to address bias caused by missing data.

RESULTS: The prevalence of CFS was 1.86% (95% confidence interval [CI]: 1.47 to 2.24). After excluding children with high levels of depressive symptoms, the prevalence was 0.60% (95% CI: 0.37 to 0.84). Authorized school absences were much higher (mean difference: 35.6 [95% CI: 26.4 to 44.9] half-day sessions per academic year) and reported depressive symptoms were much more likely (odds ratio [OR]: 11.0 [95% CI: 5.92 to 20.4]) in children with CFS than in those without CFS. Female gender (OR: 1.95 [95% CI: 1.33 to 2.86]) and family adversity (OR: 1.20 [95% CI: 1.01 to 1.42] per unit family adversity index) were also associated with CFS.

CONCLUSIONS: CFS affected 1.9% of 16-year-olds in a UK birth cohort and was positively associated with higher family adversity. Gender was a risk factor at age 16 years but not at age 13 years or in 16-year-olds without high levels of depressive symptoms.

Chronic Fatigue Syndrome at Age 16 Years, by Simon M. Collin, Tom Norris, Roberto Nuevo, Kate Tilling, Carol Joinson, Jonathan A.C. Sterne, Esther Crawley in Pediatrics,
February 2016

University of Bristol press release, 25 January: 1 in 50 16-year-olds affected by chronic fatigue syndrome

In what is believed to be the biggest study of chronic fatigue syndrome (CFS) – also known as myalgic encephalomyelitis (ME) – in children to date, researchers at the University of Bristol, have found that almost 2 per cent of 16-year-olds have CFS lasting more than six months and nearly 3 per cent have CFS lasting more than three months (the UK definition). Those with CFS missed, on average, more than half a day of school every week.

The researchers looked at the condition in 5,756 participants in Children of the 90s and found that girls were almost twice as likely as boys to have the condition. This is because CFS/ME became more common in girls between 13 and 16 but not in boys. Children from families experiencing greater adversity were more likely to have the condition, dispelling the commonly held view that CFS is a ‘middle-class’ illness or ‘yuppie-flu’. The definition of adversity included poor housing, financial difficulties and a lack of practical and/or emotional support for the mother.

The researchers point out that the diagnosis of CFS was not made by a doctor but is based on responses to questionnaires sent to both the teenagers and their parents.

BBC news reports Dr Crawley as saying that “research showed it could be successfully treated with cognitive behavioural therapy (CBT) in young people.” No link to this research was given: Chronic fatigue syndrome on rise among 16-year-olds 25 January 2016

Western Daily Press, 25 January 2016:‘Yuppie flu’ taking toll on teens

Times, 25 January 2016: One in 40 teenage girls has chronic fatigue

Sun, 25 January 2016: New research reveals that yuppie flu hits one in 50 teenagers

 

Posted in News | Tagged , , , , , , , , | 1 Comment

Plans to modernise non-emergency patient transport services

Welsh Government Press release: New plans to modernise non-emergency patient transport services in Wales unveiled, 15 January 2016

Non-emergency patient transport services in Wales will be enhanced and their operating hours extended as part of wide-ranging plans to modernise the service, Deputy Health Minister Vaughan Gething has announced.

The plans will improve quality of care through the provision of a safe and timely service which will meet the needs of individual patients and reduce pressures on the 999 emergency ambulance service.

Under the new arrangements, the Emergency Ambulance Services Committee will commission non-emergency patient transport services for health boards from April 2016 and enhanced services for oncology and renal patients by September 2016.

Other changes to be put in place by March 2017 include:

  • A national set of service standards and requirements to extend the hours of the service between 6am and 8pm Monday to Friday as well as improving the discharge and transfer of patients from all scheduled care services
  • Disaggregation of the non-emergency patient transport service from the emergency ambulance service, ensuring appropriate focus on each important patient group
  • A new non-emergency patient transport service brand.

The new plans will be delivered within the £25m budget health boards have for non-emergency patient transport services every year.

The reforms follow recommendations made by Professor Siobhan McClelland’s in her Strategic Review of Welsh Ambulance Services. They also build on the successful pilots featured in the Griffiths review of non-emergency patient transport services.

Mr Gething said:

“I am pleased to announce I have been able to agree the plans that have been developed by Wales’ health boards and the Welsh Ambulance Services NHS Trust for modernising non-emergency patient transport services in Wales.

“These plans mark a step change in the commissioning, planning and delivery of the service which will see non-emergency patient transport services delivering greater benefits for patients and NHS Wales.

“They have been developed following considerable engagement across the NHS and with trades unions, local authorities and service users.

“They have also been developed at a time when the Welsh Ambulance Service is being transformed into clinically-responsive service which sits at the heart of our unscheduled care system.”

The modernisation plans will be implemented in a phased way in order to ensure a smooth and planned transition to the new arrangements.

Posted in News | Tagged , , , | Comments Off on Plans to modernise non-emergency patient transport services

Blue badge now also available to people with cognitive impairment

Welsh Government press release, 21 December 2015: Modernising the Blue Badge Scheme 

In January 2010 we published our action plan for modernising the Blue Badge Scheme.
Following that we have worked to deliver the priorities in the action plan, which range from changes to eligibility to better enforcement,

We have extended the eligibility criteria to allow new groups of disabled people to apply for a Blue Badge (i.e. those with cognitive impairment). There have been no changes to reduce the number of people who meet the criteria.

We have also worked with local authorities and health professionals to streamline the application process.

Watch our videos on extending the eligibility criteria and on how we’re improving enforcement of the Blue Badge scheme.

Blue Badge Improvement Service (BBIS):

On 1 April 2012 we introduced the new BBIS system. It allows applicants to apply for a badge online. Applications can also be made directly to the local authority. Local authorities can share information to prevent fraud and reduce abuse of the system.

Read about the Blue Badge Improvement Scheme on the Northgate Public Services website.

Expert Review group 2013:

In 2013, the Minister for Economy, Science and Transport commissioned an Expert Review Group to review the Blue Badge scheme. The group made a number of recommendations for improving the scheme in Wales.  These recommendations included extending eligibility to people with a cognitive impairment, introducing a consistent approach to assessments and improved enforcement.

Task & Finish Review 2015:

In May 2015 the Minister for Science, Economy and Transport commissioned a Task & Finish Group to review the Blue Badge Scheme in its entirety. The group was commissioned with a remit to deliver an interim report in July and a full report of findings by November.

Posted in News | Tagged , | Comments Off on Blue badge now also available to people with cognitive impairment

Tuller discusses the nature of bias in the PACE trial

Virology blog: Trial By Error, Continued: More Nonsense from The Lancet Psychiatry
by David Tuller, 19 January 2016

The PACE authors have long demonstrated great facility in evading questions they don’t want to answer. They did this in their response to correspondence about the original 2011 Lancet paper. They did it again in the correspondence about the 2013 recovery paper, and in their response to my Virology Blog series. Now they have done it in their answer to critics of their most recent paper on follow-up data, published last October in The Lancet Psychiatry.

(They published the paper just a week after my investigation ran. Wasn’t that a lucky coincidence?)

The Lancet Psychiatry follow-up had null findings: Two years or more after randomization,  there were no differences in reported levels of fatigue and physical function between those assigned to any of the groups. The results showed that cognitive behavior therapy and graded exercise therapy provided no long-term benefits because those in the other two groups reported improvement during the year or more after the trial was over. Yet the authors, once again, attempted to spin this mess as a success.

In their letters, James Coyne, Keith Laws, Frank Twist, and Charles Shepherd all provide sharp and effective critiques of the follow-up study. I’ll let others tackle the PACE team’s counter-claims about study design and statistical analysis. I want to focus once more on the issue of the PACE participant newsletter, which they again defend in their Lancet Psychiatry response.

Here’s what they write: “One of these newsletters included positive quotes from participants. Since these participants were from all four treatment arms (which were not named) these quotes were [not]…a source of bias.”

Let’s recap what I wrote about this newsletter in my investigation. The newsletter was published in December 2008, with at least a third of the study’s sample still undergoing assessment. The newsletter included six glowing testimonials from participants about their positive experiences with the trial, as well as a seventh statement from one participant’s primary care doctor. None of the seven statements recounted any negative outcomes, presumably conveying to remaining participants that the trial was producing a 100 % satisfaction rate. The authors argue that the absence of the specific names of the study arms means that these quotes could not be “a source of bias.”

This is a preposterous claim. The PACE authors apparently believe that it is not a problem to influence all of your participants in a positive direction, and that this does not constitute bias. They have repeated this argument multiple times. I find it hard to believe they take it seriously, but perhaps they actually do. In any case, no one else should. As I have written before, they have no idea how the testimonials might have affected anyone in any of the four groups—so they have no basis for claiming that this uncontrolled co-intervention did not alter their results.

Moreover, the authors now ignore the other significant effort in that newsletter to influence participant opinion: publication of an article noting that a federal clinical guidelines committee had selected cognitive behavior therapy and graded exercise therapy as effective treatments “based on the best available evidence.” Given that the trial itself was supposed to be assessing the efficacy of these treatments, informing participants that they have already been deemed to be effective would appear likely to impact participants’ responses. The PACE authors apparently disagree.

It is worth remembering what top experts have said about the publication of this newsletter and its impact on the trial results. “To let participants know that interventions have been selected by a government committee ‘based on the best available evidence’ strikes me as the height of clinical trial amateurism,” Bruce Levin, a biostatistician at Columbia University, told me.

My Berkeley colleague, epidemiologist Arthur Reingold, said he was flabbergasted to see that the researchers had distributed material promoting the interventions being investigated, whether they were named or not. This fact alone, he noted, made him wonder if other aspects of the trial would also raise methodological or ethical concerns.

“Given the subjective nature of the primary outcomes, broadcasting testimonials from those who had received interventions under study would seem to violate a basic tenet of research design, and potentially introduce substantial reporting and information bias,” he said. “I am hard-pressed to recall a precedent for such an approach in other therapeutic trials. Under the circumstances, an independent review of the trial conducted by experts not involved in the design or conduct of the study would seem to be very much in order.”

David Tuller is academic coordinator of the concurrent masters degree program in public health and journalism at the University of California, Berkeley.

Keith R Laws responded 20 January 2016:
David – you raise a key issue concerning the PACE authors’ (lack of) response to the point in our letter about the leaflet and equipoise. The point is that the groups have quite different expectations to start with. When randomly assigned to their groups, when asked if their ‘Treatment is Logical’, those who assigned to Adaptive Pacing Therapy (APT) gave 84% endorsement, Cognitive Behavioural Therapy (CBT) 71% and Graded Exercise Therapy (GET) 84% – by contrast Specialised Medical Care (SMC) was endorsed as a ‘logical treatment’ by fewer than half – 49%. And following treatment, only 50% were satisfied with SMC compared with 82-86% for the other three conditions. Further, at the end of treatment, the proportion dissatisfied with treatment was greater in the SMC than the other three groups *combined*. This is covered in my blog.

My point is that the SMC becomes akin to a wait-list control and this is well-known to often induce detrimental effects in participants – and this is only likely to be worsened by receipt of the leaflet outlining how great everyone is doing, while those who see their assignment as logical are buoyed-up by the positive statements in the leaflet.

Nobody is arguing that the impact of a leaflet could predict the whole pattern of results – the key point is the introduction of unequivocal presence of bias …against Specialised Medical Care and in favour of the other three treatments

Posted in News | Tagged , , , , , , | Comments Off on Tuller discusses the nature of bias in the PACE trial

PINCHED – Neuron Protein Marker studied in ME/CFS

Cort Johnson reports on The Role of PINCH in Chronic Energy Deficit in the CNS.

The National CFIDS Foundation PINCH study is a timely one given the interest in neuroinflammation in ME/CFS. Hopefully over the next year we’ll get a positive brain imaging study that indicates neuroinflammation in present in chronic fatigue syndrome (ME/CFS). With the NCF’s PINCH study starting up it’s possible we could get another verification of neuroinflammation. (I’ll feel like pinching myself if that happens :))

PINCH stands for “Particularly interesting new cysteine-histidine-rich protein”. This protein has been most prominently shown to be released during HIV/AIDS infection of the brain, but has also been found in the periphery in the dorsal root ganglia after neuronal injury.

A 2011 review article stated that PINCH has been implicated in an array of diseases including kidney failure, cardiomyopathy, nervous system degeneration and demyelination, and tumorigenesis. Increased PINCH levels appear to reflect either infection or neuronal damage or both.

A 2011 study indicated that PINCH is often liberated by inflammatory cytokines produced by the microglia such as TNF-a. The increased TNF-a levels may reflect the presence of a pathogen or some other factor.

Increased levels of PINCH are also associated with a protein called hp-tau that’s often accumulated in the brains of people with neurodegenerative diseases such as Alzheimer’s, Dementia and HIV-associated brain injury. It’s not clear exactly what PINCH is doing but it appear to assist the brain in ridding itself of these dangerous proteins. It may also be trying to repair damaged neurons.

The investigator funded by the National CFIDS Foundation, Dr. Dianne Langford of Temple University, is one of the most foremost PINCH investigators.

The PINCH ME/CFS Study

National CFIDS Foundation funds Temple University Neuroscience Researcher Press Release — October 14th, 2015

The National CFIDS Foundation Inc. (NCF) is pleased to announce Dr. Dianne Langford as its latest research grant recipient. Dr. Langford is an Associate Professor of Neuroscience and Neurovirology in the Neuroscience Department at the Temple University School of Medicine in Philadelphia. Dr. Langford’s $150,019 grant is titled, “The Role of PINCH in Chronic Energy Deficit in the CNS.”

According to Alan Cocchetto, NCF Medical Director, “PINCH is a protein found in damaged neurons and is a biomarker for brain injury. Dr. Langford’s assistance has been very important to our understanding of a specific neuropathology potentially associated with CFIDS. This grant will greatly extend our preliminary efforts undertaken to date and is aimed at increasing our knowledge of the CFIDS disease process.”

Posted in News | Tagged , , , , , | Comments Off on PINCHED – Neuron Protein Marker studied in ME/CFS

Dr Fred Friedberg on the meaning of ‘recovery’ in the PACE trial

Dr Fred Friedberg, IACFS/ME President comments:

In a significant development regarding the controversial PACE trial, the largest and most influential behavioral treatment trial of CFS/ME to date, a recent open letter to the editor of the Lancet was published by a distinguished group of scientists (Davis, Edwards, Jason, Levin, Racaniello and Reingold, 2015).

The letter re-examined the reported fatigue and physical function outcomes in the trial article and also pointed out potential conflicts of interest. The letter requested an independent expert-conducted re-analysis of PACE trial data.

The letter raised significant concerns about how ‘recovery’ was defined, pointing out that recovery criteria for improved fatigue and physical functioning were so broad that many patients with impairments or no improvement were still classified as ‘recovered.’ The use of the recovery term in my view is appropriate only for those who have experienced full or near full restoration of health. Yet the data from the PACE trial did not empirically confirm such restoration for those ‘recovered’ individuals, nor did the study report on how many patients actually viewed themselves as recovered.

The terms ‘recovery’ and ‘cure’ should be carefully considered when applied to chronic illnesses. Certainly measurable improvement occurs in ME/CFS but the notion of full recovery is a much more ambitious construct for which we need proof not only from instruments, but from talking to the patients themselves.

Source: IACFS/ME Newsletter, Volume 8, Issue 3 • December 2015: Distinguished scientists address the PACE trial

Posted in News | Tagged , , , | Comments Off on Dr Fred Friedberg on the meaning of ‘recovery’ in the PACE trial